RxDoctor Payments Data

Kathryn Stevens, APRN

Family · Searcy, ARNPI 1316610173

Payments from drug & device makers

$454in general payments, 2019–2025

Across 21 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$268
  • GSK$38
  • Alkermes, Inc.$30
  • Braeburn Inc.$28
  • Sanofi-aventis U.S. LLC$27
  • Lundbeck LLC$18
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$454100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie12$268
GSK2$38
Alkermes, Inc.1$30
Braeburn Inc.1$28
Sanofi-aventis U.S. LLC1$27
Lundbeck LLC1$18
MVP Orthopedics Inc1$18
AstraZeneca1$15
Exact Sciences1$13

How this compares

$454 in reported general payments places this provider in the 55th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$4,854
Medicare patients
37
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide76$86,501
OzempicSemaglutide50$44,411
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$27,122
EliquisApixaban34$25,928
JardianceEmpagliflozin24$24,816
Bevespi AerosphereGlycopyrrolate/Formoterol Fum47$20,317
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$19,325
VraylarCariprazine Hcl11$14,530
TrulicityDulaglutide14$14,209
JanuviaSitagliptin Phosphate23$13,041
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$11,989
LinzessLinaclotide22$11,877
Emgality PenGalcanezumab-Gnlm12$9,238
BelsomraSuvorexant19$8,545
Xigduo XrDapaglifloz Propaned/Metformin11$7,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBevespi Aerosphere, Breztri Aerosphere, Symbicort$15$44,12193 claims
GSKTrelegy Ellipta$38$27,12235 claims
AbbVieVraylar, Linzess$268$26,40733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,103 family providers in Arkansas.

Other family in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →